Add time:07/21/2019         Source:sciencedirect.com

SummaryObjectivesPain and disability are the main clinical manifestations of osteoarthritis, for which only symptomatic therapies are available. Hence, there is a need for therapies that can simultaneously alter disease progression and provide pain relief. KBP is a dual amylin- and calcitonin-receptor agonist with antiresorptive and chondroprotective properties. In this study we investigated the effect of KBP in a rat model of osteoarthritis.

We also recommend Trading Suppliers and Manufacturers of CALCITONIN, RAT (cas 11118-25-5). Pls Click Website Link as below: cas 11118-25-5 suppliers